Passage Bio (PASG) vs Senti Biosciences (SNTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Passage Bio (PASG) has outperformed Senti Biosciences (SNTI) over the past year, losing 54.3% versus a loss of 81.9%. Over five years, PASG leads with a -98.1% price change compared with -99.7% for SNTI. Passage Bio is the larger company by market cap ($12.0 million vs $9.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PASG | SNTI |
|---|---|---|
| Share price | $3.73 | $0.318 |
| Market cap | $11.99M | $9.90M |
| 1-day change | -0.13% | -1.15% |
| YTD return | -67.97% | -69.07% |
| 1-year return | -54.35% | -81.93% |
| 5-year return | -98.06% | -99.68% |
| EPS (TTM) | $-11.33 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.00 | $2.88 |
| 52-week low | $3.29 | $0.29 |
| Distance from 52-week high | -81.38% | -88.96% |
| Analyst consensus | buy | none |
| Avg. price target upside | +316.11% | +4145.28% |
| Average volume | 26.11K | 573.78K |
| Shares outstanding | 3.22M | 31.15M |
| Employees | 24 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PASG has outperformed SNTI by 27.6 percentage points over the past year.
About Passage Bio
PASG stock →Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 24 employees
About Senti Biosciences
SNTI stock →Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees
PASG vs SNTI FAQ
Which is bigger, Passage Bio or Senti Biosciences?
Passage Bio (PASG) is larger, with a market capitalization of $11.99M compared with $9.90M for Senti Biosciences (SNTI).
Which stock has performed better over the past year, PASG or SNTI?
PASG returned -54.35% over the past 12 months, compared with -81.93% for SNTI (price return, excluding dividends). Past performance does not predict future results.
Are Passage Bio and Senti Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.